Article Text

PDF
Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer
  1. M Burkhardt1,*,
  2. E Mayordomo1,*,
  3. K-J Winzer2,
  4. F Fritzsche1,
  5. T Gansukh1,
  6. S Pahl1,
  7. W Weichert1,
  8. C Denkert1,
  9. H Guski1,
  10. M Dietel1,
  11. G Kristiansen1
  1. 1Institute of Pathology, Charité-Universitätsmedizin, Berlin, Germany
  2. 2Interdisciplinary Breast Centre, Charité-Universitätsmedizin
  1. Correspondence to:
    Dr Glen Kristiansen
    Institute of Pathology, Charité Hospital, Campus Mitte, Schumannstr 20/21, D-10117 Berlin, Germany; glen.kristiansen{at}charite.de

Abstract

Background: Activated leucocyte cell adhesion molecule (ALCAM, CD166) is a cell surface member of the immunoglobulin superfamily. ALCAM expression has prognostic relevance in prostate and colon cancer.

Objective: To evaluate ALCAM protein expression in breast cancer by immunohistochemistry and to correlate expression levels with clinicopathological data.

Methods: 162 primary breast carcinomas with a mean clinical follow up time of 53 months were immunostained using a monoclonal ALCAM antibody. The staining was evaluated as an immunoreactive score (IRS) and grouped into low v high for both membranous and cytoplasmic staining.

Results: Intraductal and invasive carcinomas showed a higher ALCAM expression (median IRS 4 and 6 respectively) than normal breast tissue (IRS 2). In univariate survival analyses a significant association of high cytoplasmic ALCAM expression with shortened patient disease-free survival (mean (SD) five year non-progression rate, 69.4 (4.6)% v 49.4 (11.1)%, p = 0.0142) was found. In multivariate analyses of disease-free survival times, high cytoplasmic ALCAM expression (relative risk (RR) = 2.086, p = 0.026) and nodal status (RR = 2.246, p = 0.035) were significantly associated with earlier disease progression, whereas tumour grading (RR = 1.6, p = 0.052) was of borderline significance.

Conclusions: The data suggest that strong cytoplasmic ALCAM expression in primary breast cancer, as detected by immunohistochemistry, might be a new marker for a more aggressive breast cancer biology.

  • ALCAM, activated leucocyte cell adhesion molecule
  • DCIS, ductal carcinoma in situ
  • IRS, immunoreactive score
  • breast cancer
  • ALCAM
  • prognostic marker
  • immunohistochemistry

Statistics from Altmetric.com

Footnotes

  • * These two authors contributed equally to the work

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.